Boehringer’s deal spree; Praxis’ licensing pact with Shanghai biotech; Vico Therapeutics raises $60M

Plus, news about PolyPid, Claram­e­tyx Bio­sciences, De­bio­pharm, Re­pare Ther­a­peu­tics, Im­mu­nic, Voy­ager Ther­a­peu­tics, Kymera Ther­a­peu­tics and Cat­a­lyst Phar­ma­ceu­ti­cals:

Boehringer In­gel­heim inks its third deal this week: The Ger­man biotech will pay up to €410 mil­lion in up­front and mile­stones to Ky­owa Kirin for world­wide rights to drugs for fi­bro-in­flam­ma­to­ry dis­eases. The deal fol­lows a can­cer im­munother­a­py tie-up and a liv­er dis­ease pact. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.